Altesa BioSciences reported positive Phase 2a challenge study results for vapendavir, an oral rhinovirus capsid inhibitor, showing reduced viral load and inflammation in COPD patients infected with rhinovirus. The data support vapendavir's potential to prevent rhinovirus-driven COPD exacerbations, and the company has initiated a Phase 2b CARDINAL trial to further evaluate the treatment.
Immunic Inc presented additional data from its Phase 2 CALIPER trial at the ACTRIMS Forum, showing Vidofludimus calcium reduced both acute and chronic brain lesions in progressive multiple sclerosis patients and demonstrated clinical evidence of reduced EBV reactivation.
NanoViricides is preparing to advance NV-387 into a Phase II clinical trial for Monkeypox in the Democratic Republic of Congo, with regulatory approval received and full funding secured through recent financings totaling approximately $6.2 million.
NanoViricides has filed an orphan drug designation application with the FDA for NV-387 as a measles treatment, amid rising U.S. cases that reached 2,251 in 2025 with 3 deaths and 727 cases already reported in early 2026.
